The treatment of patients with myasthenia gravis.
Although there is general agreement among experienced physicians on the usefulness of different treatments for myasthenia gravis (MG), so many variations are possible that in practice, similar patients treated by different physicians rarely are treated the same. Because of these divergent opinions one may read papers in reputable journals that present and propose extremely variable programs for treating MG. Scientific controversies, although stimulating, often result in confusion, especially for less experienced physicians seeking treatment guidelines for their patients. This article offers the authors' opinions on the benefits and limitations of the therapeutic modalities used in MG and their proposals of therapeutic plans for specific situations.
Sanders
D B
DB
Department of Medicine, Duke University Medical School, Durham, North Carolina.
Scoppetta
C
C
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010956:Plasmapheresis; D013934:Thymectomy
D000305:Adrenal Cortex Hormones; D002800:Cholinesterase Inhibitors; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents